Zelminemab (AMG-301) 是一种人单克隆抗体，可抑制 I 型 PACAP (PAC1) 受体。
| 生物活性 | Zelminemab (AMG-301) is a human monoclonal antibody that inhibitsPACAP type I (PAC1) receptor[1]. |
体内研究
(In Vivo) | Zelminemab（10 mg/kg；i.v.；一次）降低 TCC 中的伤害性神经元活动[2]。
| Animal Model: | Sprague-Dawley rats, electricalstimulation was performed on the intact dura mater abovethe middle meningeal artery[2]. | | Dosage: | 10 mg/kg | | Administration: | i.v.; once | | Result: | Induced an inhibition of stimulus-evoked nociceptive activity in the trigeminocervical com-plex (TCC). |
|
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
